• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Korea·Healthcare·214450.KQ
Share

PharmaResearch Co., Ltd. Stocks

₩ 290000Last Updated 23.06.2026

Issuer Rating

4/7
Performance

Favourable

Risk

Moderate

Recommendation

Hold

Market Cap

₩ 1.99B

₩ 290000
Key Takeaways

Risk factor

High price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Excellent growth

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

PharmaResearch Co., Ltd., a biopharmaceutical company based in Seongnam, South Korea, was established in 1993. The firm offers a diverse portfolio of products, including pharmaceuticals, medical devices, and functional foods. Its product range features Re-An eye drops, designed to shield eyes from various types of corneal damage. For tissue regeneration, PharmaResearch provides the Rejuvenex injection, an activator for connective tissues such as ligaments, tendons, and skin, along with Rejuvenex cream, which promotes rapid wound healing. A significant portion of its offerings falls under the REJURAN brand, focusing on advanced skin care. This includes REJURAN HEALER, an intradermal injection enhancing skin elasticity, turgidity, and tonicity, complemented by Rejuran i and Rejuran s injections (administered intradermally or via cannula). The REJURAN line also extends to daily protective moisturizer, a specialized concentrate for sensitive and aging skin, healing eye gel, healing creams and masks, a UV-protective sunscreen, and a soothing recovery mask. Additionally, the company manufactures the D+CELL 350 TRA series, a comprehensive collection of rejuvenation and repair solutions, encompassing concentrated creams, intensive serums, activating facial toners, high-potency eye lifts, moisture balancers, masks, as well as hair and hydro products. Other notable items include the REJURAN tone-up booster and various medical devices, such as CLEVIEL prime plus and contour plus (both containing lidocaine), and CONJURAN medical devices. Diversifying its operations, PharmaResearch also produces functional foods marketed under the REJULINE, REJUSHINE, and REJULIGHT brand names. The company adopted its current name, PharmaResearch Co., Ltd., in April 2021, having previously been known as Pharma Research Products Co., Ltd.

Company Valuation

Fairly valued
4/7

Based on key historical and expected multiples, the stock is fairly valued relative to its peers. In particular, the stock is reasonably priced on P/E, of fair value on E

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of 214450.KQ is 481096 and suggests 63.9% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

24.06.2026 07:00

Alphabet will be added to the Dow Jones Blue Chip Index. Its stock price has doubled over the past year

24.06.2026 01:47

The boom in the prediction market has prompted Meta to create its own app — NYT

24.06.2026 01:09

The Nasdaq fell 2%, with volatility hitting a two-year high: a look back at the day's sell-off in the tech sector

24.06.2026 00:50

The dollar rose to its highest level since November: Traders are betting on a Fed rate hike

23.06.2026 23:45

Cathie Wood's company bought SpaceX shares on the day the stock fell 16%. Should you do the same?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026